Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Blis MD vs Corsica Health

Blis MD
Graded #74

Higher grade

vs+6.400000000000006
Corsica Health
Graded #188

Lower grade

The verdict

Blis MD takes it — 72.7/100 to 66.3/100.

Blis MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Blis MD is a US telehealth offering personalized GLP-1 weight-loss treatment with compounded semaglutide and tirzepatide, prescribed after a free virtual consultation with a licensed provider.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBlis MD +40
88
48
Dose & formulationCorsica Health +5
72
77
Clinical oversightCorsica Health +13
74
87
Labs & monitoringBlis MD +8
62
54
FulfillmentCorsica Health +10
65
75
Contract termsEven
55
55
Blis MD · left barCorsica Health · right bar

The numbers

MetricBlis MDCorsica Health
WeighScore72.7/10066.3/100
GradeCC
Scorecard rank#74#188
Semaglutide$139/mo$249/mo (compounded)
Tirzepatide$199/mo$349/mo (compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Blis MD

Graded #74 · C

Strengths

  • Transparent flat monthly pricing published upfront (139 dollars semaglutide, 199 dollars tirzepatide)
  • Free initial virtual consultation with a licensed provider
  • Both semaglutide and tirzepatide offered with ongoing provider check-ins

Where it loses points

  • Compounding pharmacy is not named publicly
  • States served are not listed on the site
  • Thin public trust signals (no LegitScript seal or named medical director found)
Corsica Health

Graded #188 · C

Strengths

  • Public pricing shown for both compounded and brand-name options — a real transparency advantage
  • $1,499/mo brand-name Wegovy/Ozempic/Mounjaro is below typical retail cash-pay
  • LegitScript Certified
  • Clear 3-step intake: Assessment, Provider Review, Receive Medication
  • $199/mo compounded semaglutide and $249/mo compounded tirzepatide (3-month plans) are competitively priced

Where it loses points

  • Legal entity name and state of incorporation not disclosed on the site
  • Pharmacy partner described only as a 'licensed compounding pharmacy,' not named
  • Per-state availability not listed publicly
  • First-month promotional pricing not disclosed
  • Lab-work inclusion not clearly disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard